Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock
Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Aug 13, 2024
Trial Information
Current as of May 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether a continuous infusion of a medication called terlipressin, combined with norepinephrine, can improve outcomes for patients suffering from acute kidney injury due to acute on chronic liver failure and septic shock. Septic shock is a serious condition where the body’s response to infection leads to dangerously low blood pressure. Norepinephrine is commonly used to help raise blood pressure, but this trial aims to see if adding terlipressin can provide additional benefits.
To participate in this trial, patients must be over 18 years old and under 60, have been diagnosed with acute on chronic liver failure, and be experiencing acute kidney injury along with needing norepinephrine to manage their blood pressure. Patients with certain conditions, such as severe heart or kidney issues, or those who have received terlipressin recently, will not be eligible. Participants will receive close monitoring and care throughout the trial, helping researchers determine the safety and effectiveness of this treatment combination.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age\>18 years and \<60 yrs
- • 2. ACLF as per APASL
- • 3. AKI according to KDIGO Criteria
- • 4. septic shock requiring norepinephrine (\<0.05mcg/kg/min).
- Exclusion Criteria:
- • 1. Septic shock requiring 2 vasopressors (Norephinephrine reuirement \> 0.05mcg/kg/min)
- • 2. Symptomatic cardiopulmonary disease
- • 3. Chronic kidney disease
- • 4. Peripheral vascular disease
- • 5. Hepatocellular carcinoma outside Milan criteria
- • 6. Prior use of terlipressin in last 48 hours
- • 7. Patients with hypovolemic or hemorrhagic shock
- • 8. Patients already meeting criteria for dialysis or with history of dialysis in last 7 days
- • 9. Intrinsic kidney disease, Acute tubular necrosis with urinary output \< 400 ml /day or obstructive uropathy
- • 10. History of immunosuppressive drugs
- • 11. Pregnancy
- • 12. Human immunodeficiency virus 1 and 2
- • 13. Portal vein thrombus
About Institute Of Liver And Biliary Sciences, India
The Institute of Liver and Biliary Sciences (ILBS) in India is a premier research and healthcare institution dedicated to the advancement of knowledge and treatment in liver, biliary, and related diseases. As a clinical trial sponsor, ILBS is committed to conducting innovative and ethically-driven research to improve patient outcomes and enhance therapeutic options in hepatology. The institute fosters collaboration among multidisciplinary teams of clinicians, researchers, and healthcare professionals, ensuring rigorous scientific methodologies and adherence to regulatory standards. Through its focus on translational research, ILBS aims to bridge the gap between laboratory discoveries and clinical applications, ultimately contributing to the global understanding and management of liver diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, Delhi, India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported